Board of Directors
Michel Orsinger is the Chairman of AO Invest and has held various global leadership positions in the Consumer and Healthcare/Med Tech industries—including Novartis (Divisional President), Synthes (CEO & President) and Johnson & Johnson (Worldwide Executive Chairman Global Orthopedics DePuy Synthes). Orsinger is now an investor, board member of various start-ups, advisor to a Private Equity company and Member of the Board of Takeda. Orsinger studied at the University of St. Gallen and attended management programs at Harvard Business School and INSEAD.
Amitai Ziv is a medical doctor and senior hospital management executive with strong experience in the field of patient safety and simulation-based medical education. Prof Ziv is the Director of the Rehabilitation Hospital and Associate Dean for Education at the Sheba Medical Center, Tel Hashomer, Israel, as well as the Founder and Director of MSR, the Israel Center for Medical Simulation. Over the years Ziv has worked with many startups, supporting them with medical simulation and education expertise.
Daniel Buchbinder is an oral and maxillofacial surgeon and currently Professor and Chief at the Division of Maxillofacial Surgery, Department of Otolaryngology–Head & Neck Surgery, Mount Sinai Beth Israel Hospital, New York, US. Buchbinder is a former Chair of the Department of Dentistry and Oral, Maxillofacial Surgery, Mount Sinai Medical Center. Buchbinder has published more than 70 peer-reviewed articles.
Beat Merz is Managing Director and Head of European Equity, New Harbor Venture Partners LLC based in Zurich, Switzerland. Merz has a PhD in biomechanics from the ETH in Zurich, and an MBA from the University of Strathclyde. He has strong life sciences, medical technology and medical device experience as an investor, entrepreneur and executive manager. Merz also has extensive experience in venture capital and equity financing and operations and has managed investments in the US, Europe and Israel.
Gerhard Ries is Managing Partner at LifeCare Partners, Basel, Switzerland. He has a PhD and MSc in molecular biology from the University of Basel, and a diploma in biotechnology from Fachhochschule Weihenstephan. Ries has extensive experience evaluating target companies, managing investments and serving on boards. With a strong pharma, biotech and consulting background, Ries has led and executed investments in almost 40 companies in twelve years.
Ulf Claesson has, over the last 25 years, created and rapidly built sustainable businesses for large corporations, industrial investors and VCs in the Americas, Europe and Asia. Claesson has a senior executive background with Hewlett-Packard and IBM, managed spin-outs from Intuit and Ericsson, and has initiated more than a dozen merger and acquisition transactions to-date. Claesson is also a member of European and US company boards, and various innovation initiatives. In addition he is a lecturer at the Department of Management, Technology, and Economics of the ETH Zurich.